Spots Global Cancer Trial Database for Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Official Title: A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer

Study ID: NCT04778982

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

KN026 combined with Palbociclib and Fulvestrant

Study Description

Brief Summary: This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with palbociclib and fulvestrant in women or male with HER2-positive metastatic breast cancer .The subjects will receive 20 mg/kg IV Q2W+ palbociclib 100/125 mg/day orally+/-Fulvestrant 500 mg IM until progressive disease, unacceptable toxicity or death.

Detailed Description: KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.